tiprankstipranks
Larimar Therapeutics, Inc. (LRMR)
NASDAQ:LRMR
US Market
LRMR
Larimar Therapeutics
RESEARCH TOOLSreports
Want to see LRMR full AI Analyst Report?

Larimar Therapeutics (LRMR) Stock News & Sentiment

1,109 Followers
Larimar Shareholders Approve Governance and Capital Structure Changes
Premium
Company Announcements
Larimar Shareholders Approve Governance and Capital Structure Changes
2d ago
8K
LRMR
Larimar Therapeutics: Buy Rating Backed by Superior Nomlabofusp Data and Favorable Risk-Reward Versus Design Therapeutics
Premium
Ratings
Larimar Therapeutics: Buy Rating Backed by Superior Nomlabofusp Data and Favorable Risk-Reward Versus Design Therapeutics
3d ago
LRMR
Larimar Therapeutics Reaffirmed as Buy on Nomlabofusp Progress and Regulatory De-Risking; $25 Price Target Maintained
Premium
Ratings
Larimar Therapeutics Reaffirmed as Buy on Nomlabofusp Progress and Regulatory De-Risking; $25 Price Target Maintained
6d ago
LRMR
Myles Minter Reiterates Buy on Larimar as Nomlabofusp Advances Toward 2026 BLA and Potential First Disease‑Modifying FA Therapy by 2027
Premium
Ratings
Myles Minter Reiterates Buy on Larimar as Nomlabofusp Advances Toward 2026 BLA and Potential First Disease‑Modifying FA Therapy by 2027
7d ago
LRMR
Larimar Details Q1 Results and Nomlabofusp Regulatory Progress
Premium
Company Announcements
Larimar Details Q1 Results and Nomlabofusp Regulatory Progress
7d ago
8K
LRMR
LRMR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
LRMR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
17d ago
LRMR
Nomlabofusp’s Manageable Risk, Strong Efficacy Signals, and Significant FA Market Upside Underpin Buy Rating on LRMR
Premium
Ratings
Nomlabofusp’s Manageable Risk, Strong Efficacy Signals, and Significant FA Market Upside Underpin Buy Rating on LRMR
2M ago
LRMR
More LRMR News >

LRMR News on the Web

Larimar Shareholders Approve Governance and Capital Structure Changes
TipRanks News
Neutral
Larimar Therapeutics: Buy Rating Backed by Superior Nomlabofusp Data and Favorable Risk-Reward Versus Design Therapeutics
TipRanks News
Bullish
Larimar Therapeutics price target lowered to $12 from $13 at Wedbush
TipRanks News
Bullish
Larimar Therapeutics Reaffirmed as Buy on Nomlabofusp Progress and Regulatory De-Risking; $25 Price Target Maintained
TipRanks News
Bullish
Larimar’s Upcoming Regulatory Milestones and Strong Balance Sheet Highlight Momentum in Friedreich’s Ataxia Program
Market Chameleon
Bullish
Myles Minter Reiterates Buy on Larimar as Nomlabofusp Advances Toward 2026 BLA and Potential First Disease‑Modifying FA Therapy by 2027
TipRanks News
Bullish
Larimar Therapeutics reports Q1 EPS (31c), consensus (57c)
TipRanks News
Bullish
Larimar Details Q1 Results and Nomlabofusp Regulatory Progress
TipRanks News
Neutral

News Score - Last 7 Days

Very Positive
LRMR
Sector Average
Media Buzz
This Week6 articles
Weekly Average1.25 articles
News Sentiment
This Week99%
Sector Average77%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is LRMR’s Media Buzz Sentiment?
6 articles about LRMR were published this week. In an average week, 1.25 articles are published.
    What is LRMR’s weekly average amount of articles?
    In an average week, 1.25 articles about LRMR are published.
      What is LRMR’s News Sentiment?
      99% of articles about LRMR were positive this week, compared to its sector average of 77%.
        Healthcare Stocks that are Trending in the News
        RLAYRelay Therapeutics
        GOSSGossamer Bio
        IMVTImmunovant
        ROIVRoivant Sciences
        PROKProKidney
        Showing the stocks with the most bullish news sentiment over the past week